Online citations, reference lists, and bibliographies.
← Back to Search

Immunization With The Chlamydia Trachomatis Major Outer Membrane Protein, Using The Outer Surface Protein A Of Borrelia Burgdorferi As An Adjuvant, Can Induce Protection Against A Chlamydial Genital Challenge.

S. Pal, C. Luke, A. Barbour, E. Peterson, L. M. de la Maza
Published 2003 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Two strains of mice C3H/HeN (H-2(k)) and BALB/c (H-2(d)) were immunized with the Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP) using the Borrelia burgdorferi outer surface protein A (OspA) as an adjuvant. As a control, groups of mice were inoculated with ovalbumin instead of MOMP. Female mice were immunized using three different routes: intramuscular (i.m.) plus subcutaneous (s.c.), intranasal (i.n.) and perivaginal and perisacral (p.vag.+p.sac.). Significant humoral and cell mediated immune responses developed particularly in mice inoculated by the i.m.+s.c. routes as determined by the levels of chlamydial specific antibody in the serum and genital secretions and a T-cell proliferative assay. Following immunization the animals were challenged in the genital tract with C. trachomatis MoPn and the course of the infection followed by vaginal cultures. Significant protection against infection was achieved in the C3H/HeN mice inoculated i.m.+s.c. with MOMP+OspA, as shown by the intensity and duration of vaginal cultures, and by the number of mice with positive cultures. On the other hand in BALB/c mice there was only a decrease in the number of animals with positive vaginal cultures. Six weeks after the challenge the mice were mated and the outcome of the pregnancy evaluated. In both the C3H/HeN and the BALB/c mice immunized i.m.+s.c. with MOMP+OspA there was significant protection against infertility as shown by the number of animals with bilateral fertility and number of embryos per uterine horn. In conclusion, immunization using C. trachomatis MOMP, and B. burgdorferi OspA as an adjuvant, can induce significant protection against a chlamydial genital challenge.
This paper references
10.1126/SCIENCE.95.2454.49-A
AN UNIDENTIFIED VIRUS WHICH PRODUCES PNEUMONIA AND SYSTEMIC INFECTION IN MICE.
C. Nigg (1942)
10.1093/INFDIS/132.1.87
New knowledge of chlamydiae and the diseases they cause.
J. T. Grayston (1975)
Human chlamydial infections
J. Schachter (1978)
10.1097/00007435-197804000-00011
The potential for vaccine against infection of the genital tract with Chlamydia trachomatis.
Grayston Jt (1978)
10.1136/jcp.33.3.205
The rôle of Chlamydia trachomatis in genital-tract and associated diseases.
D. Taylor-Robinson (1980)
10.1111/J.1574-6968.1981.TB07622.X
Progesterone as a key factor in the development of a mouse model for genital-tract infection with Chlamydia trachomatis
M. Tuffrey (1981)
10.1128/iai.31.3.1161-1176.1981
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis
H. Caldwell (1981)
10.1128/iai.44.1.82-85.1984
Immune response in mice infected in the genital tract with mouse pneumonitis agent (Chlamydia trachomatis biovar)
A. Barron (1984)
10.1128/JB.169.9.3879-3885.1987
Diversity of Chlamydia trachomatis major outer membrane protein genes
R. Stephens (1987)
10.1084/JEM.170.4.1271
Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein
R. Morrison (1989)
10.1001/JAMA.1991.03470180065039
Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000.
Washington Ae (1991)
10.1093/CLIND/13.SUPPLEMENT_11.S892
Introduction: objectives of herpes simplex virus vaccines seen from a historical perspective.
B. Roizman (1991)
10.1016/0378-1119(91)90579-Z
Sequence of the gene encoding the major outer membrane protein of the mouse pneumonitis biovar of Chlamydia trachomatis.
T. Fielder (1991)
10.1016/0163-4453(92)91882-C
Chlamydial vaccines--future trends.
M. Ward (1992)
10.1530/JRF.0.0950031
Genetic susceptibility to chlamydial salpingitis and subsequent infertility in mice.
M. Tuffrey (1992)
10.1097/00007435-199207000-00001
Pelvic Inflammatory Disease and Fertility: A Cohort Study of 1,844 Women with Laparoscopically Verified Disease and 657 Control Women with Normal Laparoscopic Results
L. Weström (1992)
10.1128/iai.61.1.81-90.1993
Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA
L. Erdile (1993)
10.1128/iai.62.8.3354-3362.1994
Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis
S. Pal (1994)
10.1128/iai.62.5.2094-2097.1994
Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility
L. M. de la Maza (1994)
10.1073/PNAS.91.26.12594
The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen) receptor.
H. Fuchs (1994)
Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones.
M. Piccinni (1995)
10.1016/0264-410X(95)80022-6
A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections.
Michael de la Maza (1995)
10.1002/jlb.59.3.442
Progesterone inhibits inducible nitric oxide synthase gene expression and nitric oxide production in murine macrophages
Lance Miller (1996)
Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection.
X. Yang (1996)
10.1016/0020-2452(96)85299-7
Prospects for a vaccine against Chlamydia genital disease I. — Microbiology and pathogenesis
P. Bavoil (1996)
10.1128/iai.65.8.3361-3369.1997
Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge
S. Pal (1997)
10.1016/S0264-410X(97)00219-3
Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.
C. Luke (1997)
10.1016/0968-0004(90)90136-y
Protein structure : a practical approach
T. Creighton (1997)
10.1093/INFDIS/175.1.91
An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
C. Luke (1997)
10.1016/S0264-410X(96)00183-1
Adjuvants--a classification and review of their modes of action.
J. Cox (1997)
10.1016/S0264-410X(96)00295-2
OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.
L. Erdile (1997)
10.1126/SCIENCE.281.5377.703
Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.
D. Gross (1998)
The role of CD14 in signaling mediated by outer membrane lipoproteins of Borrelia burgdorferi.
R. M. Wooten (1998)
10.1056/NEJM199807233390402
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.
L. Sigal (1998)
Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2.
M. Hirschfeld (1999)
10.1007/PL00000641
Cellular and molecular aspects of Lyme arthritis
D. Gross (2000)
10.1128/IAI.68.7.4207-4216.2000
Effects of Estradiol and Progesterone on Susceptibility and Early Immune Responses to Chlamydia trachomatis Infection in the Female Reproductive Tract
C. Kaushic (2000)
10.1128/IAI.69.8.5203-5206.2001
Susceptibility of Mice to Vaginal Infection withChlamydia trachomatis Mouse Pneumonitis Is Dependent on the Age of the Animal
Sukumar Pal (2001)
10.1128/IAI.69.10.6240-6247.2001
Immunization with the Chlamydia trachomatis Mouse Pneumonitis Major Outer Membrane Protein Can Elicit a Protective Immune Response against a Genital Challenge
Sukumar Pal (2001)



This paper is referenced by
10.1038/s41541-021-00312-9
A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
A. Olsen (2021)
10.1016/j.jvacx.2018.100002
The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei
E. R. Lafontaine (2019)
10.3389/fimmu.2019.01577
Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses
R. Pais (2019)
10.3389/fimmu.2017.00230
Salmonella Typhi Porins OmpC and OmpF Are Potent Adjuvants for T-Dependent and T-Independent Antigens
M. Pérez-Toledo (2017)
10.1016/j.ttbdis.2015.04.009
Broad diversity of host responses of the white-footed mouse Peromyscus leucopus to Borrelia infection and antigens.
Vanessa J. Cook (2015)
10.1128/CMR.00105-13
Genital Chlamydia trachomatis: Understanding the Roles of Innate and Adaptive Immunity in Vaccine Research
S. Vasilevsky (2014)
10.2147/IJN.S44155
Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine
Stacie J. Fairley (2013)
against Chlamydia A Novel Recombinant Multisubunit Vaccine
J. Igietseme (2013)
10.1586/erv.12.25
Microneedle and mucosal delivery of influenza vaccines
S. Kang (2012)
10.1016/j.vaccine.2011.12.125
Vaccination of healthy and diseased koalas (Phascolarctos cinereus) with a Chlamydia pecorum multi-subunit vaccine: evaluation of immunity and pathology.
A. Kollipara (2012)
10.1093/infdis/jir552
Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.
A. Slepenkin (2011)
10.1155/2011/963513
Chlamydia trachomatis Vaccine Research through the Years
K. Schautteet (2011)
10.1586/erv.11.139
Chlamydia vaccines: recent developments and the role of adjuvants in future formulations
J. Igietseme (2011)
10.1016/j.vaccine.2011.01.031
Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31®.
Chun-mei Cheng (2011)
10.2217/fmb.10.148
Towards a Chlamydia trachomatis vaccine: how close are we?
M. Cochrane (2010)
10.1128/IAI.00881-10
Vaccination against Chlamydia Genital Infection Utilizing the Murine C. muridarum Model
Christina M. Farris (2010)
10.1111/j.1574-695X.2008.00493.x
A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.
E. Ekong (2009)
Genital tract CD4 + T cells for vaccination and protection against Chlamydia trachomatis
Ellen Marks (2009)
Modulated by Liver X Receptor Activation-Independent Signaling and Is Reciprocally Formation Requires MyD 88-Dependent and-Induced Foam Cell Chlamydia pneumoniae
M. Arditi (2008)
10.4049/jimmunol.181.10.7186
Chlamydia pneumoniae-Induced Foam Cell Formation Requires MyD88-Dependent and -Independent Signaling and Is Reciprocally Modulated by Liver X Receptor Activation1
Shuang Chen (2008)
10.1038/mi.2007.19
Chlamydia trachomatis infection: host immune responses and potential vaccines
L. Hafner (2008)
10.1007/978-1-4020-8412-6_16
Immunity Against Chlamydia trachomatis
E. Marks (2008)
10.1186/1471-2180-8-136
CCL5 regulation of mucosal chlamydial immunity and infection
Senthilkumar K. Sakthivel (2008)
10.1139/O06-211
Codon usage bias in Chlamydia trachomatis and the effect of codon modification in the MOMP gene on immune responses to vaccination.
Y. Zheng (2007)
10.1016/J.TVJL.2004.09.006
Vaccination against chlamydial infections of man and animals.
D. Longbottom (2006)
10.1016/J.VACCINE.2005.08.074
Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge.
S. Pal (2006)
10.1016/J.VACCINE.2005.08.097
Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
S. Singh (2006)
10.1038/nri1551
Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine
R. Brunham (2005)
10.1074/jbc.M503225200
MyD88 Is Pivotal for the Early Inflammatory Response and Subsequent Bacterial Clearance and Survival in a Mouse Model of Chlamydia pneumoniae Pneumonia*
Y. Naiki (2005)
10.1016/J.VACCINE.2005.05.042
Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomatis.
A. Solomon (2005)
10.1517/17425247.2.3.549
Delivery of Chlamydia vaccines
J. Igietseme (2005)
Chlamydia trachomatis genital infection: Immunity and prospects for vaccine development
L. Alonso (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar